Our top pick for
Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure
Ultragenyx Pharmaceutical Inc is a biotechnology business based in the US. Ultragenyx Pharmaceutical shares (RARE) are listed on the NASDAQ and all prices are listed in US Dollars. Ultragenyx Pharmaceutical employs 893 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$78.22|
|52-week range||$75.83 - $179.65|
|50-day moving average||$89.32|
|200-day moving average||$95.15|
|Wall St. target price||$139.74|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-5.40|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-15)||-2.23%|
|1 month (2021-09-24)||-17.76%|
|3 months (2021-07-23)||-5.44%|
|6 months (2021-04-23)||-28.81%|
|1 year (2020-10-23)||-15.95%|
|2 years (2019-10-24)||94.24%|
|3 years (2018-10-24)||42.09%|
|5 years (2016-10-24)||18.57%|
|Revenue TTM||$359.4 million|
|Gross profit TTM||$-147,183,000|
|Return on assets TTM||-14.85%|
|Return on equity TTM||-42.14%|
|Market capitalisation||$5.3 billion|
TTM: trailing 12 months
There are currently 4.0 million Ultragenyx Pharmaceutical shares held short by investors – that's known as Ultragenyx Pharmaceutical's "short interest". This figure is 3.8% up from 3.9 million last month.
There are a few different ways that this level of interest in shorting Ultragenyx Pharmaceutical shares can be evaluated.
Ultragenyx Pharmaceutical's "short interest ratio" (SIR) is the quantity of Ultragenyx Pharmaceutical shares currently shorted divided by the average quantity of Ultragenyx Pharmaceutical shares traded daily (recently around 396860.1980198). Ultragenyx Pharmaceutical's SIR currently stands at 10.1. In other words for every 100,000 Ultragenyx Pharmaceutical shares traded daily on the market, roughly 10100 shares are currently held short.
However Ultragenyx Pharmaceutical's short interest can also be evaluated against the total number of Ultragenyx Pharmaceutical shares, or, against the total number of tradable Ultragenyx Pharmaceutical shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Ultragenyx Pharmaceutical's short interest could be expressed as 0.06% of the outstanding shares (for every 100,000 Ultragenyx Pharmaceutical shares in existence, roughly 60 shares are currently held short) or 0.0977% of the tradable shares (for every 100,000 tradable Ultragenyx Pharmaceutical shares, roughly 98 shares are currently held short).
A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Ultragenyx Pharmaceutical.
Find out more about how you can short Ultragenyx Pharmaceutical stock.
We're not expecting Ultragenyx Pharmaceutical to pay a dividend over the next 12 months.
Ultragenyx Pharmaceutical's shares were split on a 1:3 basis on 16 January 2014. So if you had owned 3 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Ultragenyx Pharmaceutical shares – just the quantity. However, indirectly, the new 200% higher share price could have impacted the market appetite for Ultragenyx Pharmaceutical shares which in turn could have impacted Ultragenyx Pharmaceutical's share price.
Over the last 12 months, Ultragenyx Pharmaceutical's shares have ranged in value from as little as $75.83 up to $179.647. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Ultragenyx Pharmaceutical's is 1.8201. This would suggest that Ultragenyx Pharmaceutical's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Ultragenyx Pharmaceutical Inc. , a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in the United States. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; and Dojolvi for treating long-chain fatty acid oxidation disorders. The company is also developing DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy product candidate for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co. , Ltd.
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Everything we know about the Progressive Care IPO, plus information on how to buy in.
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.